Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role?

Table 1 Main characteristics of patients and tumors of the study (modified from Sartori et al[52])

Patients	Primary tumor	LM before 1st LA	Total LM treated	Diameter range (mm)	No. of LA sessions	Months of FU	HP	Out-come	Cause of death
1	Pancreas	3	3	14-24	1	82	No	Dead	Larynx cancer
2	Sm. bowel	6	6	7-26	1	39	Yes	Dead	HP + EP
3	Colon	3	3	9-21	1	55	No	Dead	Stroke
4	Sm. bowel	6	13	5-25	3	38	No	Dead	Colon cancer
5	Pancreas	7	7	12-28	1	12	Yes	Dead	HP + EP
6	Sm. bowel	3	3	12-24	1	21	No	Dead	EP
7	Pancreas	22	37	5-21	5	99	No	Alive	--
8	Sm. bowel	6	18	5-35	5	36	Yes	Dead	HP + EP
9	Sm. bowel	3	3	12-31	1	87	No	Alive	--
10	Pancreas	3	3	11-24	1	26	Yes	Dead	HP + EP
11	Lung	9	23	6-26	4	37	No	Dead	EP
12	Pancreas	8	11	6-30	2	73	Yes	Alive	--
13	Sm. bowel	8	12	5-20	3	31	No	Dead	Endocarditis
14	Colon	6	8	6-23	2	71	Yes	Alive	--
15	Sm. bowel	6	11	9-25	2	40	Yes	Dead	HP + EP
16	Pancreas	5	5	8-26	1	55	Yes	Alive	--
17	Lung	6	8	9-28	2	49	No	Alive	--
18	Pancreas	3	3	10-25	1	25	No	Alive	--
19	Sm. bowel	4	4	8-22	1	24	No	Alive	--
20	Adrenal	4	4	6-24	1	24	No	Alive	--
21	Sm. bowel	4	4	11-28	1	22	Yes	Alive	--

LA: Laser ablation; LM: Liver metastases; HP: Hepatic progression; EP: Extrahepatic progression.